Pharmacy Review for Income Protection Claims

Strengthen IP claims assessment through specialist medication review

Published: 3 April 2026 | Updated: 3 April 2026

Why Income Protection Claims Require Medication Assessment

Income protection claims hinge on your assessment of functional capacity and return-to-work feasibility. Medical records provide the baseline. But medication management is central to actual functional capacity. A claimant prescribed high-dose sedating medications may have lower cognitive or physical capacity than their diagnosis suggests. Conversely, appropriate medication management may enable work capacity that raw diagnosis would not predict.

Your claims assessors work from diagnoses and medical letters. They don't see the pharmacy-level detail: whether medications are appropriate, whether dosing is evidence-based, whether side effects are limiting work capacity, and whether deprescribing could improve function. You need specialist pharmacy review to provide this clarity. IMM's pharmacist-led assessments give you objective medication analysis that informs your IP claims decisions.

What IMM Reviews in Income Protection Claims

Medication Impact on Cognitive and Physical Function

Many medications directly impair the cognitive and physical capacity needed for work. We assess each medication's side effect profile and identify which agents are limiting function. Sedating medications, cognitive-impairing drugs, balance-affecting agents, and others create functional limitations independent of the underlying condition.

Dosing Appropriateness for Work Capacity

Doses often reflect clinical treatment goals, not work capacity. We benchmark doses against evidence and identify where doses exceed what is necessary or where function-impairing side effects could be minimised through dose reduction. High doses of non-essential medications directly impair work capacity.

Deprescribing and Return-to-Work Potential

Many claimants take medications that are no longer necessary or that were appropriate initially but impair recovery and return to work. We identify deprescribing opportunities and provide evidence-based plans that could improve functional capacity and work feasibility.

Medication-Related Barriers to Occupational Rehabilitation

Medication side effects often prevent claimants from engaging with physiotherapy, psychological support, or vocational rehabilitation. We identify which medications may be creating these barriers and recommend adjustments that could enable rehabilitation participation and faster return to work.

Drug Interactions and Safety in Return-to-Work Context

Some claimants take medication combinations that create safety risks in a work context. Drug interactions that impair concentration, balance, or cognitive function may make return to specific occupations unsafe. We identify these risks and assess work feasibility accordingly.

How Pharmacy Review Informs IP Claims Decisions

Real-World Example: IP Claim Assessment

Scenario: A 42-year-old IT professional lodges an income protection claim following a motor accident. Current medications: oxycodone 20mg twice daily, pregabalin 300mg daily, amitriptyline 75mg at night, alprazolam 2mg daily (in divided doses), and paracetamol as needed. Medical records show "significant" pain and anxiety, with treating GP noting "severe functional limitation." Claimant reports inability to concentrate, poor sleep despite zopiclone-equivalent doses, and marked fatigue. Your functional capacity assessor questions whether the claimant's functional limitation is proportional to the documented injury or whether medication side effects are the primary barrier.

IMM Review Findings: Oxycodone at 40mg daily is high for the documented injury type; alone creates sedation and cognitive impairment. Pregabalin 300mg daily is at the upper therapeutic range and adds further cognitive blunting. Amitriptyline 75mg at night is a higher dose causing morning sedation and daytime cognitive impairment. Alprazolam 2mg daily in divided doses is a high dose, contraindicated for long-term use, and creates dependence risk plus significant cognitive and balance impairment. Together, these medications create a medication burden that is almost certainly the primary barrier to cognitive work. Deprescribing and dose reduction could meaningfully improve function.

Outcome: Your claims assessor now understands that medication burden, not the injury alone, is limiting the claimant's work capacity. Rehabilitation plan includes coordinated deprescribing: reduce oxycodone, reduce pregabalin, reduce amitriptyline, and taper alprazolam with medical support. Within 3-4 months, claimant experiences significant functional improvement and successfully transitions back to part-time work. IP claim duration reduced; early return to work achieved through medication management optimisation.

Common IP Claims: Medication Assessment Focus

Back pain and musculoskeletal claims: Often involve opioids, gabapentinoids, and muscle relaxants. Pharmacy review identifies whether medication burden is the primary barrier to return to work, and whether deprescribing could enable rehabilitation.

Mental health claims (depression, anxiety): Medication regime complexity and dose appropriateness are key assessment factors. Review identifies whether medications are appropriately dosed for stability, and whether medication side effects (sedation, cognitive impairment, sexual dysfunction) are limiting work capacity.

Neurological claims (headache, migraine, post-concussion): Medication overuse headache is a common problem in these claims. Pharmacy review identifies whether frequent pain medication use is perpetuating rather than treating the condition, and whether deprescribing is indicated.

Fatigue and functional limitation claims: Often medication-driven (sedating antidepressants, benzodiazepines, antihistamines, high-dose analgesics). Review identifies medication-driven fatigue and opportunities for improvement through deprescribing or dose reduction.

Practical Implementation for Your IP Claims Process

Step 1: Identify candidates - Claims with complex medications, sedating agents, or high doses that may be impairing function.

Step 2: Request review - When functional capacity is assessed or return-to-work planning occurs, refer for pharmacy review to inform rehabilitation planning.

Step 3: Coordinate outcomes - Use IMM's deprescribing recommendations to inform rehabilitation planning. Coordinate rehabilitation with medication adjustment to maximize functional improvement.